Report me for selling fake medicine? Why are you crying when your illness relapses?

It would be very risky for Novartis to acquire this formula directly with cash.

From clinical trials to market approval, how big is the final market and how much of the market can be monopolized?

Each of these links has certain risks. No matter how high the success rate is, there is still a possibility of failure.

If there is a problem in any one of the links, it is very likely that all the money will be lost.

Billions of dollars of investment could be wiped out in a matter of minutes.

Moreover, it is not just the heavy losses.

If there were only 300 billion yuan, it might not be enough to impress Chen Xuan and allow him to successfully sell the formula.

But this transaction is different through equity exchange.

Novartis shares are valuable, but ultimately they are just paper figures.

If you get a new drug formula through equity trading, the stock price may skyrocket and all the investment will be recovered at once.

The most important thing is that after exchanging 3% of the shares, even if the new drug fails in the end, the loss will not be too great, as long as Chen Xuan and Antai Pharmaceutical Group are in control

There is still a great chance to earn back the money lost now, which is relatively safer.

The 300 billion yuan spent to acquire the formula for a special lung cancer drug is likely to be lost without a penny left.

But if you pay 3% of the shares to trade, the protection will be much greater, with multiple insurances.

Among them, Chen Xuan is the biggest insurance.

Even if this miracle drug fails, he can still develop another miracle drug.

Or he could find out the reason why the special medicine failed, and then make targeted improvements, and finally release better special effect news.

As the developer of a miracle drug, he is the most likely to do this.

But if the formula of the special medicine is acquired by Novartis, he will have no obligation to cooperate in improving the formula.

Therefore, Anna is indeed very smart. She can think of this method, which seems to be a premium acquisition, but it actually leaves Novartis with countless big insurances.

It is almost a sure win position.

For this kind of insurance, this premium is naturally nothing.

However, she is very sincere in giving a valuation of 700 billion yuan.

If Chen Xuan agrees to this cooperation plan, he can get 3% of Novartis's shares, but he also has to hand over 60% of Antai Pharmaceutical Group's shares.

3% of the shares may not sound like much, but it is worth 60 billion US dollars. If the shares are sold, more than 400 billion can be obtained.

Of course, this kind of trading agreement will definitely have restrictions, such as how long it will take before the stocks can be cashed out, and how much can be cashed out each time. There will be additional details.

If there were no restrictions, Novartis would simply sell its shares and trade with Chen Xuan.

The reason for trading shares this time is to bet that Chen Xuan's holdings in Lehua can push Novartis's stock price to a new high.

After all, if he wants to make Novartis shares more valuable, he needs to make Aetna Pharmaceuticals as valuable as possible.

Because Antai Pharmaceutical Group's shares are held by Novartis, the more valuable the former is, the more valuable the shares held by the latter will become, which will be reflected in the latter's stocks.

The 40% stake in Chen Xuan's hands will allow her to continue working hard instead of giving up on developing new drugs.

"Actually, I'm very interested in your plan."

"But unfortunately, I have no intention of transferring the patents and shares now."

"It's not that this plan is bad, but I have no intention of transferring it. In other words, no matter how good the conditions are, I will not agree to it."

Faced with Anna's plan, Chen Xuan could only clearly express his rejection.

If he wanted to transfer the new drug patent and shares, she would definitely agree to this condition.

To be fair, this condition is indeed very favorable. Anna has her own calculations, but she has also clearly given a premium, which is very sincere.

Even he had to admit this.

Novartis is indeed much more sincere than Changfeng Group and AbbVie.

But unfortunately, he never thought about transferring his shares. Even if the conditions were good, it would not change the result.

"what?"

"Is that so?"

"That would be a shame."

Anna was slightly stunned when she received Chen Xuan's clear rejection.

She didn't expect to be rejected so bluntly by Chen Xuan.

But the good thing is that Chen Xuan is not unwilling to sell his shares because he is not satisfied with the price, he simply does not want to transfer them.

In other words, Novartis did not get the formula for the lung cancer drug, nor did it get shares in Aetna Pharmaceuticals Group, so other competitors could not get them either.

This is the most important point. If competitors get it, it will pose a huge threat to Novartis.

So, even though she was rejected, she was still a little relieved, at least it was not the worst outcome.

……